API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/aclaris-lays-46-staff-resurrects-zunsemetinib-potential-cancer-treatment
https://www.globenewswire.com//news-release/2023/11/13/2778890/37216/en/Aclaris-Therapeutics-Announces-Top-line-Results-from-12-Week-Phase-2b-Trial-of-Oral-Zunsemetinib-ATI-450-for-Moderate-to-Severe-Rheumatoid-Arthritis-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2023/06/13/2687010/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2b-Study-of-Oral-Zunsemetinib-ATI-450-for-Moderate-to-Severe-Rheumatoid-Arthritis-ATI-450-RA-202.html